Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$52.37
-1.8%
$49.11
$21.72
$54.60
$10.01B1.252.95 million shs6.03 million shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$2.73
-4.2%
$2.55
$1.83
$7.48
$2.58B0.38.20 million shs19.98 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$25.24
-0.8%
$27.73
$23.15
$67.96
$9.82B1.9310.95 million shs18.32 million shs
Qiagen N.V. stock logo
QGEN
Qiagen
$45.98
+0.5%
$48.27
$37.63
$51.88
$10.22B0.641.38 million shs1.82 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+4.20%+1.39%+9.04%+27.80%+105.43%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
+3.26%+10.04%+25.00%-0.70%-16.67%
Moderna, Inc. stock logo
MRNA
Moderna
+1.80%+0.24%-8.81%-1.74%-63.57%
Qiagen N.V. stock logo
QGEN
Qiagen
+0.68%-0.67%-6.93%-2.07%+3.01%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$52.37
-1.8%
$49.11
$21.72
$54.60
$10.01B1.252.95 million shs6.03 million shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$2.73
-4.2%
$2.55
$1.83
$7.48
$2.58B0.38.20 million shs19.98 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$25.24
-0.8%
$27.73
$23.15
$67.96
$9.82B1.9310.95 million shs18.32 million shs
Qiagen N.V. stock logo
QGEN
Qiagen
$45.98
+0.5%
$48.27
$37.63
$51.88
$10.22B0.641.38 million shs1.82 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+4.20%+1.39%+9.04%+27.80%+105.43%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
+3.26%+10.04%+25.00%-0.70%-16.67%
Moderna, Inc. stock logo
MRNA
Moderna
+1.80%+0.24%-8.81%-1.74%-63.57%
Qiagen N.V. stock logo
QGEN
Qiagen
+0.68%-0.67%-6.93%-2.07%+3.01%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
3.00
Buy$63.9422.10% Upside
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
3.20
Buy$10.75293.77% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.05
Hold$41.8165.66% Upside
Qiagen N.V. stock logo
QGEN
Qiagen
2.27
Hold$49.698.06% Upside

Current Analyst Ratings Breakdown

Latest IBRX, QGEN, BBIO, and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/15/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$70.00
9/12/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$72.00 ➝ $82.00
9/10/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$8.00
9/8/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$24.00
9/3/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$55.00 ➝ $70.00
8/29/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$56.00 ➝ $70.00
8/26/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$24.00
8/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetUnderperform$18.00 ➝ $15.00
8/14/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$24.00
8/7/2025
Qiagen N.V. stock logo
QGEN
Qiagen
Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
8/7/2025
Qiagen N.V. stock logo
QGEN
Qiagen
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$48.00 ➝ $50.00
(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$235.81M42.46N/AN/A($7.71) per share-6.79
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$14.74M175.07N/AN/A($0.57) per share-4.79
Moderna, Inc. stock logo
MRNA
Moderna
$3.06B3.21N/AN/A$28.33 per share0.89
Qiagen N.V. stock logo
QGEN
Qiagen
$2.04B5.01$3.24 per share14.17$16.05 per share2.86
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$535.76M-$4.09N/AN/AN/A-329.25%N/A-85.69%11/11/2025 (Estimated)
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$413.56M-$0.48N/AN/AN/A-648.57%N/A-113.86%11/11/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$7.53N/AN/AN/A-94.31%-25.96%-20.09%11/6/2025 (Estimated)
Qiagen N.V. stock logo
QGEN
Qiagen
$83.59M$1.6927.1718.692.4018.30%14.77%8.87%11/5/2025 (Estimated)

Latest IBRX, QGEN, BBIO, and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.83-$0.95-$0.12-$0.95$98.46 million$110.57 million
8/5/2025Q2 2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.10-$0.10N/A-$0.10$21.95 million$26.43 million
8/5/2025Q2 2025
Qiagen N.V. stock logo
QGEN
Qiagen
$0.60$0.60N/A$0.44$523.97 million$533.54 million
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.99-$2.13+$0.86-$2.13$116.26 million$142.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Qiagen N.V. stock logo
QGEN
Qiagen
$0.250.54%N/A14.79%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
5.19
5.08
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/A
4.11
3.98
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.93
3.77
Qiagen N.V. stock logo
QGEN
Qiagen
0.25
1.61
1.35

Institutional Ownership

CompanyInstitutional Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
8.58%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Qiagen N.V. stock logo
QGEN
Qiagen
70.00%

Insider Ownership

CompanyInsider Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
18.20%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
76.79%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Qiagen N.V. stock logo
QGEN
Qiagen
9.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400191.17 million156.38 millionOptionable
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
590945.26 million219.39 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800389.08 million346.28 millionOptionable
Qiagen N.V. stock logo
QGEN
Qiagen
5,765222.29 million202.29 millionOptionable

Recent News About These Companies

QIAGEN N.V. $QGEN Shares Sold by Acadian Asset Management LLC
Strs Ohio Makes New Investment in QIAGEN N.V. $QGEN
Financial Comparison: QIAGEN (NYSE:QGEN) and Polyrizon (NASDAQ:PLRZ)
7 Hot Healthcare Stocks To Buy Right Now

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$52.37 -0.96 (-1.80%)
Closing price 04:00 PM Eastern
Extended Trading
$53.26 +0.90 (+1.71%)
As of 05:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

ImmunityBio stock logo

ImmunityBio NASDAQ:IBRX

$2.73 -0.12 (-4.21%)
Closing price 04:00 PM Eastern
Extended Trading
$2.74 +0.02 (+0.55%)
As of 06:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Moderna stock logo

Moderna NASDAQ:MRNA

$25.24 -0.21 (-0.83%)
Closing price 04:00 PM Eastern
Extended Trading
$25.26 +0.02 (+0.08%)
As of 06:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Qiagen stock logo

Qiagen NYSE:QGEN

$45.98 +0.24 (+0.52%)
Closing price 03:59 PM Eastern
Extended Trading
$45.94 -0.04 (-0.10%)
As of 05:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.